Radioiodine Whole-Body Scintigraphy & SPECT/CT

Radioiodine whole-body scintigraphy images residual and metastatic thyroid tissue after thyroidectomy for differentiated thyroid cancer, and the physics of the radionuclide you choose shapes the entire study. I-123 and I-131 differ in half-life, photon energy, collimator, and absorbed dose, and adding single-photon emission computed tomography with CT (SPECT/CT) to the planar scan improves where, and how confidently, iodine-avid disease is localized.

Differentiated thyroid cancer (DTC) is unusual among cancers because the tumor cells retain the thyroid's ability to concentrate iodine. That single physiologic fact makes radioiodine both an imaging agent and a therapy, and it makes the nuclear medicine physicist's choices — radionuclide, collimator, energy window, planar versus SPECT/CT — directly consequential for staging and management. This guide explains the imaging physics of I-123 and I-131, why diagnostic and post-therapy scans differ, what SPECT/CT adds, and how the study is framed by NRC medical-use rules. DRPS supports facilities with this work through its PET/CT and nuclear medicine physics and radiation safety officer services.

Introduction

The defining property of differentiated thyroid cancer is iodine avidity: papillary and follicular thyroid cells, and the cancers that arise from them, take up and organify iodine. After total thyroidectomy, radioiodine is used to ablate the residual normal-thyroid remnant and to treat iodine-avid metastases, and radioiodine imaging is used to find that tissue in the first place.¹

A whole-body scan performed with radioactive iodine therefore answers questions no anatomic study can: not just where there is a mass, but where there is functioning, iodine-concentrating thyroid tissue. The study depends on three physics-driven choices — which iodine radionuclide to administer, which collimator and energy window to image it with, and whether to add SPECT/CT — and on the endocrinology that primes uptake, namely thyroid-stimulating hormone (TSH) stimulation and a low-iodine diet.¹²

This article walks through the decay physics of I-123 and I-131, the collimator and energy-window consequences, the phenomenon of "stunning," the added value of SPECT/CT, the difference between a diagnostic and a post-therapy scan, and the NRC regulatory framing of these administrations.

Topic Explanation

Two radionuclides, two different imaging problems

I-123 and I-131 are both iodine, taken up identically by thyroid tissue, but they are very different photons to image. The choice between them is the first and most consequential physics decision in the study.

• I-123 decays by electron capture with a physical half-life of about 13.2 hours and emits a principal gamma ray at 159 keV. It has no particulate (beta) emission of consequence, so it deposits relatively little absorbed dose in the tissue it images, and its 159 keV photon is well matched to a standard low-energy high-resolution (LEHR) collimator.⁹
• I-131 decays by beta-minus emission with a physical half-life of about 8.02 days and emits a principal gamma ray at 364 keV. The beta particle is what makes I-131 a therapy; for imaging it means more absorbed dose, and the 364 keV gamma is penetrating enough to require a high-energy collimator to control septal penetration.⁹

For the broader family of radionuclides used in nuclear medicine, see common PET and radiopharmaceutical-therapy isotopes, and for the collimator physics behind the 364 keV challenge, see septal penetration and high-energy collimation.

Diagnostic scan versus post-therapy scan

There are two distinct whole-body scans in DTC management, and they are not interchangeable.

• A diagnostic scan uses a low activity of I-123 or I-131 before radioiodine therapy, to assess the size of the remnant and to look for iodine-avid disease that might change the treatment plan.
• A post-therapy (post-ablation) scan is acquired several days after the much larger therapeutic I-131 activity has been given. Because far more activity is present, the post-therapy scan is generally the more sensitive of the two for revealing additional foci.¹²

Priming uptake: TSH and the low-iodine diet

Thyroid cells concentrate iodine through the sodium–iodide symporter, and that uptake is driven by TSH. Before a radioiodine scan or therapy, TSH is deliberately raised — either by thyroid hormone withdrawal or by administering recombinant human TSH (rhTSH) — to maximize uptake and scan sensitivity. A low-iodine diet beforehand reduces the pool of stable dietary iodine competing with the radioiodine, improving the fraction taken up.¹

Key Technical Principles

I-123 versus I-131 for the diagnostic scan

The table summarizes the physics that drives the diagnostic-scan choice. The absorbed-dose and "stunning" differences follow directly from the decay modes.

Decay data for I-123 and I-131 are tabulated in standard nuclear-decay references such as ICRP Publication 107 and the NIST/National Nuclear Data Center evaluations.⁹¹⁰

Stunning: a real phenomenon with a debated clinical weight

"Stunning" is a reduction in the uptake of a subsequent therapeutic I-131 dose, attributed to cell damage from the diagnostic radioiodine activity given beforehand.⁵ The concern is that a diagnostic scan could blunt the effectiveness of the therapy it precedes — which is a central argument for using I-123, whose lack of a beta particle makes stunning unlikely.

The evidence, however, is more nuanced than the rationale suggests. A prospective comparison of diagnostic imaging with 14.8 MBq (0.4 mCi) of I-123 versus 74 MBq (2 mCi) of I-131 before 3.7 GBq (100 mCi) remnant ablation found no significant difference in ablation rates (81% versus 74%, p > 0.05), concluding that if stunning occurred at that diagnostic I-131 activity it had no significant clinical correlate.⁵ The practical takeaway is that I-123 is preferred to avoid the possibility of stunning, but the phenomenon should be presented as a debated effect rather than a settled determinant of outcome.

Worked example: why I-123 imaging is a same-day study

Radioactive decay follows an exponential law. For an initial activity $A_0$ and physical half-life $T_{1/2}$, the activity remaining after time $t$ is:

For I-123 with $T_{1/2}=13.2$ hours, the decay constant is:

The fraction of administered activity remaining at 24 hours is:

So only about 28% of the administered I-123 remains one day after administration — which is why I-123 whole-body imaging is performed on a same-day or next-morning schedule. By contrast, I-131 with an 8.02-day half-life retains most of its activity for days, allowing the delayed imaging (typically several days post-administration) that a post-therapy scan requires.

Energy windows and collimators

Each radionuclide is imaged with a symmetric photopeak energy window centered on its principal photon and a collimator matched to that energy. I-123 is acquired around its 159 keV photopeak with an LEHR collimator, which gives the best spatial resolution. I-131 is acquired around its 364 keV photopeak with a high-energy collimator; using a lower-energy collimator would allow 364 keV photons to penetrate the septa, producing star artifacts and degraded resolution. The collimator choice is therefore not a convenience but a determinant of image quality and quantitative accuracy — the same principle discussed in our guide to gamma camera collimator selection.

Clinical Impact

Adding SPECT/CT to a planar whole-body scan changes management in a meaningful minority of patients by improving where, and how confidently, iodine-avid disease is localized. Planar imaging shows that uptake exists; SPECT/CT shows what and where it is, fusing the functional radioiodine image onto cross-sectional CT anatomy.

The strongest summary evidence is a systematic review and meta-analysis of 30 studies, which found that adding SPECT/CT to whole-body scanning increased the proportion of conclusive readings — with lesion-based improvements of 14% for cervical, 20% for extracervical, and 18% overall — and changed treatment plans in 30% of patients after diagnostic scans and 9% after post-therapy scans, albeit on low-quality evidence.⁶ Dedicated series reinforce this: in 320 post-thyroidectomy patients, preablation diagnostic I-131 planar plus SPECT/CT detected regional metastases in 35% and distant metastases in 8%, and changed staging in 4% of patients under 45 years and 25% of patients 45 and older.⁸

SPECT/CT also reduces false positives. Physiologic radioiodine activity in the salivary glands, nasopharynx, stomach, and bladder, and benign findings, can mimic metastatic foci on planar images; the fused CT lets the reader attribute uptake to a normal structure rather than disease.⁷ For the physics of the fused acquisition, see SPECT/CT attenuation correction and PET/CT and SPECT/CT image registration and fusion.

Practical Optimization Tips

1. Match the collimator and window to the radionuclide

Use an LEHR collimator and the 159 keV window for I-123, and a high-energy collimator and the 364 keV window for I-131. A high-energy photon imaged through the wrong collimator is the most common avoidable source of degraded radioiodine images.

2. Choose the radionuclide for the clinical question

I-123 gives cleaner diagnostic images at lower dose and avoids the stunning question; low-activity I-131 may be used where I-123 logistics are impractical. Reserve high-activity I-131 imaging for the post-therapy scan.

3. Confirm TSH stimulation and low-iodine preparation

A scan performed without adequate TSH elevation or after recent iodine load (contrast, amiodarone, dietary iodine) can be falsely negative. Verify preparation before administering activity.

4. Add SPECT/CT over equivocal regions

Reserve SPECT/CT for the neck and any equivocal planar focus; it is where the localization and false-positive benefit is greatest.

5. Document the administered activity and decay timing

Record administered activity, administration time, and imaging delay so uptake and any quantitative work are defensible and the study is reproducible.

Common pitfalls to avoid

• Imaging I-131 with a low- or medium-energy collimator, producing septal-penetration artifacts.
• Confusing the diagnostic and post-therapy scans, or expecting diagnostic-scan sensitivity from a low activity.
• Reading planar uptake as disease without SPECT/CT when physiologic uptake is the likelier explanation.
• Scanning without confirmed TSH elevation or after an iodine load, risking a false-negative study.
• Overstating stunning as a settled effect rather than a debated one.

Regulatory Considerations

Radioiodine administrations are medical use of byproduct material, regulated by the NRC under 10 CFR Part 35 or by the equivalent Agreement State program, with dose limits set by 10 CFR Part 20. How a given administration is handled depends on the radionuclide and activity.

• 10 CFR 35.200 covers imaging and localization studies for which a written directive is not required — this cleanly covers I-123 (and Tc-99m) diagnostic imaging.¹¹
• A written directive is required for any I-131 sodium iodide dosage greater than 1.11 MBq (30 microcuries), which includes typical diagnostic whole-body-scan activities; those administrations are handled under the 35.300 medical-use provisions with the associated written-directive and dosage-determination requirements.¹¹
• Patient release applies to the therapy context, not low-activity diagnostic imaging. Under 10 CFR 35.75, a patient may be released if the total effective dose equivalent to any other individual is not likely to exceed 5 mSv (0.5 rem), with written ALARA instructions required if the dose to another individual could exceed 1 mSv (0.1 rem). NRC Regulatory Guide 8.39 is the implementing guidance.¹²¹³

Of the states DRPS serves, Florida, Maryland, Virginia, California, Nevada, New York, Pennsylvania, and New Jersey are NRC Agreement States that license medical use under their own radiation-control rules, while Washington, DC and Delaware are regulated directly by the NRC. A facility must confirm which authority issues its license and which requirements apply. For related safety topics, see I-131 thyroid cancer therapy and radiation safety and thyroid uptake measurement.

Frequently Asked Questions (FAQs)

What is a radioiodine whole-body scan?

A radioiodine whole-body scan is a nuclear medicine imaging study that uses radioactive iodine, either I-123 or I-131, to image functioning thyroid tissue throughout the body. After thyroidectomy for differentiated thyroid cancer, it is used to detect residual thyroid remnant and iodine-avid metastatic disease, because normal and cancerous thyroid cells concentrate iodine.

Why choose I-123 instead of I-131 for a diagnostic scan?

I-123 is a pure gamma emitter with a 159 keV photon and about a 13 hour half-life, so it delivers less absorbed dose to thyroid tissue and gives cleaner images with a low-energy collimator. I-131 emits a therapeutic beta particle and a high-energy 364 keV gamma and has an eight-day half-life, so diagnostic I-131 deposits more dose and needs a high-energy collimator. I-123 is the common diagnostic choice to minimize possible stunning of iodine-avid tissue.

What is radioiodine stunning?

Stunning is a reduction in the uptake of a subsequent therapeutic I-131 dose that is attributed to cell damage from the diagnostic radioiodine activity given beforehand. It is a reason I-123 is often preferred for diagnostic imaging, though the clinical significance of stunning at typical diagnostic I-131 activities is debated in the literature.

What does SPECT/CT add to a planar whole-body scan?

SPECT/CT fuses the functional radioiodine image with cross-sectional CT anatomy. It improves localization of iodine-avid foci, distinguishes physiologic or benign uptake from true disease, and improves nodal and distant-metastasis staging. A systematic review found that adding SPECT/CT to whole-body scanning increased conclusive readings and changed management in a meaningful minority of patients.

How is a diagnostic scan different from a post-therapy scan?

A diagnostic scan uses a low activity of I-123 or I-131 before therapy to assess remnant and disease. A post-therapy, or post-ablation, scan is acquired several days after the much higher therapeutic I-131 activity has been administered; because far more activity is present, the post-therapy scan is generally more sensitive for detecting additional iodine-avid foci.

Does a diagnostic radioiodine scan require a written directive?

It depends on the radionuclide and activity. I-123 and most diagnostic imaging agents fall under 10 CFR 35.200, which does not require a written directive. Any I-131 sodium iodide dosage greater than 1.11 MBq (30 microcuries), which includes typical diagnostic whole-body-scan activities, requires a written directive under NRC rules and is handled under the 35.300 medical-use provisions.

How does TSH stimulation help the scan?

Elevated thyroid-stimulating hormone (TSH) increases iodine uptake by thyroid tissue, improving scan sensitivity. TSH is raised either by thyroid hormone withdrawal or by recombinant human TSH, and a low-iodine diet beforehand reduces competition from stable dietary iodine so the radioiodine is taken up more avidly.

Key Takeaways

• The radionuclide choice is a physics decision. I-123 (159 keV, ~13 h, no beta) images at low dose with an LEHR collimator; I-131 (364 keV, ~8 days, therapeutic beta) needs a high-energy collimator and deposits more dose.
• Stunning is real but debated. It motivates using I-123, yet a prospective comparison found no significant ablation-rate difference against diagnostic I-131.
• Diagnostic and post-therapy scans differ. The post-therapy scan, acquired after the high therapeutic activity, is generally more sensitive.
• SPECT/CT improves localization and staging. It increases conclusive reads, cuts false positives, and changes management in a meaningful minority — especially in older patients.
• Regulatory handling depends on radionuclide and activity. I-123 imaging is 35.200; I-131 sodium iodide above 1.11 MBq (30 µCi) requires a written directive under 35.300.

Conclusion

Radioiodine whole-body scintigraphy works because differentiated thyroid cancer keeps the thyroid's appetite for iodine, and the quality of the study rests on physics choices the nuclear medicine team makes deliberately. Selecting I-123 or I-131 sets the collimator, the energy window, the absorbed dose, and the stunning question. Adding SPECT/CT converts "there is uptake" into "here is the disease," improving staging and reducing false positives. And the NRC framework determines whether a given administration needs a written directive. A program that treats these as connected decisions — not defaults — produces scans that are clean, defensible, and genuinely useful for managing thyroid cancer.

How DRPS Can Help

Diagnostic Radiation Physics Services supports nuclear medicine and thyroid-cancer programs with gamma camera and SPECT/CT acceptance and performance testing, collimator and energy-window verification, radioiodine imaging protocol review, and radiation safety program and written-directive support, all performed by board-certified medical physicists. This work is offered through our PET/CT and nuclear medicine physics, radiation safety officer, and radioactive material license support services.

DRPS serves facilities across our service locations, including Florida, Maryland, Virginia, Washington DC, California, Nevada, New York, Pennsylvania, New Jersey, and Delaware. A strong radioiodine imaging program protects the patient, the staff, and the integrity of the staging that drives treatment.

Related Resources

• Common PET & RPT isotopes
• Septal penetration and high-energy collimation
• SPECT/CT attenuation correction
• I-131 thyroid cancer therapy and radiation safety
• Thyroid uptake measurement
• PET/CT & SPECT/CT image registration and fusion
• PET/CT and nuclear medicine physics
• Radiation Safety Officer consulting

References

1. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1-133. doi:10.1089/thy.2015.0020. PubMed
2. Avram AM, Giovanella L, Greenspan B, et al. SNMMI Procedure Standard/EANM Practice Guideline for Nuclear Medicine Evaluation and Therapy of Differentiated Thyroid Cancer: Abbreviated Version. J Nucl Med. 2022;63(6):15N-35N. PubMed
3. Silberstein EB, Alavi A, Balon HR, et al. The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0. J Nucl Med. 2012;53(10):1633-1651. doi:10.2967/jnumed.112.105148. PubMed
4. Luster M, Clarke SE, Dietlein M, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35(10):1941-1959. doi:10.1007/s00259-008-0883-1. PubMed
5. Silberstein EB. Comparison of outcomes after 123I versus 131I pre-ablation imaging before radioiodine ablation in differentiated thyroid carcinoma. J Nucl Med. 2007;48(7):1043-1046. doi:10.2967/jnumed.107.040311. PubMed
6. Chong A, Seo Y, Bang J-I, et al. Clinical Implications of Adding SPECT/CT to Radioiodine Whole-Body Scan in Patients With Differentiated Thyroid Cancer: A Systematic Review and Meta-analysis. Clin Nucl Med. 2024;49(3):215-225. doi:10.1097/RLU.0000000000004953. PubMed
7. Avram AM. Radioiodine scintigraphy with SPECT/CT: an important diagnostic tool for thyroid cancer staging and risk stratification. J Nucl Med. 2012;53(5):754-764. doi:10.2967/jnumed.111.104133. PubMed
8. Avram AM, Fig LM, Frey KA, Gross MD, Wong KK. Preablation 131-I scans with SPECT/CT in postoperative thyroid cancer patients: what is the impact on staging? J Clin Endocrinol Metab. 2013;98(3):1163-1171. doi:10.1210/jc.2012-3630. PubMed
9. International Commission on Radiological Protection. ICRP Publication 107: Nuclear Decay Data for Dosimetric Calculations. Annals of the ICRP. 2008;38(3). icrp.org
10. National Institute of Standards and Technology / National Nuclear Data Center. Radionuclide decay data (I-123, I-131). nndc.bnl.gov
11. U.S. Nuclear Regulatory Commission. 10 CFR Part 35: Medical Use of Byproduct Material. ecfr.gov
12. U.S. Nuclear Regulatory Commission. 10 CFR Part 20: Standards for Protection Against Radiation. ecfr.gov
13. U.S. Nuclear Regulatory Commission. Regulatory Guide 8.39, Revision 1: Release of Patients Administered Radioactive Material. 2020. nrc.gov